TR200201169T2 - 2- (4,6-Dimethylpyrimidinyl-2-oxy) -3- [2- (3,4-dimethoxyphenyl) ethoxy] -3,3-diphenylpropionate and endothelin as an antagonist - Google Patents

2- (4,6-Dimethylpyrimidinyl-2-oxy) -3- [2- (3,4-dimethoxyphenyl) ethoxy] -3,3-diphenylpropionate and endothelin as an antagonist

Info

Publication number
TR200201169T2
TR200201169T2 TR2002/01169T TR200201169T TR200201169T2 TR 200201169 T2 TR200201169 T2 TR 200201169T2 TR 2002/01169 T TR2002/01169 T TR 2002/01169T TR 200201169 T TR200201169 T TR 200201169T TR 200201169 T2 TR200201169 T2 TR 200201169T2
Authority
TR
Turkey
Prior art keywords
dimethylpyrimidinyl
diphenylpropionate
endothelin
dimethoxyphenyl
antagonist
Prior art date
Application number
TR2002/01169T
Other languages
Turkish (tr)
Inventor
Jansen Rolf
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of TR200201169T2 publication Critical patent/TR200201169T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Bulus, formül (I)'e ait kati kristalli formda bir bilesik ve bunun karistirilmis ETA/ETB endotelin alici antagonistleri olarak kullanilmasi ile ilgilidir.(FORMÜL I)The invention relates to a compound of the formula (I) in the solid crystalline form and its use as mixed receptor antagonists of the ETA / ETB endothelium (FORMUL I).

TR2002/01169T 1999-10-27 2000-10-17 2- (4,6-Dimethylpyrimidinyl-2-oxy) -3- [2- (3,4-dimethoxyphenyl) ethoxy] -3,3-diphenylpropionate and endothelin as an antagonist TR200201169T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19951671A DE19951671A1 (en) 1999-10-27 1999-10-27 2- (4,6-Dimethyl-pyrimidin-2-yloxy) -3- (2- (3,4-dimethoxyphenyl) ethoxy) -3,3-diphenylpropionic acid sodium salt and its use as an endothelin antagonist

Publications (1)

Publication Number Publication Date
TR200201169T2 true TR200201169T2 (en) 2002-09-23

Family

ID=7927001

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/01169T TR200201169T2 (en) 1999-10-27 2000-10-17 2- (4,6-Dimethylpyrimidinyl-2-oxy) -3- [2- (3,4-dimethoxyphenyl) ethoxy] -3,3-diphenylpropionate and endothelin as an antagonist

Country Status (17)

Country Link
EP (1) EP1228047A1 (en)
JP (1) JP2003512460A (en)
KR (1) KR20020047301A (en)
CN (1) CN1384822A (en)
AU (1) AU1272701A (en)
BG (1) BG106700A (en)
BR (1) BR0015112A (en)
CA (1) CA2389012A1 (en)
CZ (1) CZ20021485A3 (en)
DE (1) DE19951671A1 (en)
HU (1) HUP0203476A3 (en)
IL (1) IL149312A0 (en)
MX (1) MXPA02004071A (en)
NO (1) NO20021986D0 (en)
SK (1) SK5962002A3 (en)
TR (1) TR200201169T2 (en)
WO (1) WO2001030767A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2656017T3 (en) 2004-06-24 2018-02-22 Vertex Pharmaceuticals Incorporated Conveyor modulators of the ATP binding cassette

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636046A1 (en) * 1996-09-05 1998-03-12 Basf Ag New carboxylic acid derivatives, their production and use as mixed ET¶A¶ / ET¶B¶ receptor antagonists

Also Published As

Publication number Publication date
BG106700A (en) 2003-02-28
AU1272701A (en) 2001-05-08
CA2389012A1 (en) 2001-05-03
CN1384822A (en) 2002-12-11
NO20021986L (en) 2002-04-26
HUP0203476A2 (en) 2003-05-28
SK5962002A3 (en) 2002-09-10
KR20020047301A (en) 2002-06-21
IL149312A0 (en) 2002-11-10
DE19951671A1 (en) 2001-05-03
BR0015112A (en) 2002-10-29
CZ20021485A3 (en) 2003-06-18
WO2001030767A1 (en) 2001-05-03
JP2003512460A (en) 2003-04-02
HUP0203476A3 (en) 2003-07-28
EP1228047A1 (en) 2002-08-07
MXPA02004071A (en) 2002-10-11
NO20021986D0 (en) 2002-04-26

Similar Documents

Publication Publication Date Title
BR0115400A (en) Piperazinylpyrazine compounds acting as serotonin 5ht-2 receptor agonists or antagonists
BRPI0606455A (en) pharmaceutical compounds
MXPA04003795A (en) Pyrimidine compound and medicinal composition thereof.
NO20022683L (en) Urea compounds with muscarinic receptor antagonist activity
ATE286897T1 (en) MORPHOLINE DERIVATIVES AS ANTAGONISTS AT OREXIN RECEPTORS
AP9901442A0 (en) 4-(2-Keto-1-benzimidazolinyl) piperidine compounds as orl1-receptor agonists.
TR200101155T2 (en) 4-Aroil Piperidine CCR-3 Receptor Antagonists III
CY1110243T1 (en) NPYY5 COMPETITORS
HUP0302435A2 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and pharmaceutical compositions containing them
AR018168A1 (en) NOCICEPTINE ANTAGONIST THAT INCLUDES AN AMIDA DERIVATIVE, PHARMACEUTICAL AND ANALGESIC COMPOSITION THAT INCLUDES IT, USE OF SUCH DERIVATIVE OF AMIDA AND COMMERCIAL PACKAGING THAT INCLUDES SUCH PHARMACEUTICAL COMPOSITION
DK1200426T3 (en) Substituted thien-3-yl-sulfonylamino (thio) carbonyl-thiazoline (thi) ones
TR200101893T2 (en) 4-oxo-1,4 dihydro -3-quinolinecarboxamides as antiviral agents.
MXPA06012595A (en) Amino-tetrazoles analogues and methods of use.
TR200002298A2 (en) 1,2,4,5- Tetrahydro-Benzo [D] azepines
YU39803A (en) Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2-receptor
TR200102540T2 (en) Heterocyclic compositions, intermediates and elastase inhibitors.
EA200301317A1 (en) DERIVATIVES OF AMINOHINOLINE AND ITS APPLICATION AS A3 LOSE Adenosine Ligands
HRP20010630B1 (en) 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists
TR200201169T2 (en) 2- (4,6-Dimethylpyrimidinyl-2-oxy) -3- [2- (3,4-dimethoxyphenyl) ethoxy] -3,3-diphenylpropionate and endothelin as an antagonist
TR200003652T2 (en) Tetrahydroquinoline derivatives as glycine antagonists.
TR200101654T2 (en) Vitronectin receptor antagonists
MXPA05009988A (en) 6-sulfonamide quinoline and chromene derivative as androgen receptor antagonists.
ATE374189T1 (en) PHTHALAZINONE DERIVATIVES AS PDE 4 INHIBITORS
BR9806875A (en) Process for the preparation of a compound.
TR200402754T4 (en) New benzosultam oxazolidinone antibacterial agents.